Recollections of the 60th Annual ASH Meeting and Expo

Jim Omel |

ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]

ASH 2018: My Final Thoughts, Links, and Thanks!

Robin Tuohy |

While this year’s ASH had 939 abstracts about multiple myeloma, I agree with Linda Huguelet that this year was a building year, and no real blockbusters. However, and it’s a big however, because there are many future blockbusters expected from the early phase 1 trials as they continue forward, I encourage that you pay attention […]

With Myeloma, Even a 20-year Survivor Always Has More to Learn

Yelak Biru |

Anytime you can reduce dexamethasone (dex), do it  There was one specific trial that was presented at this year’s ASH that studied the benefit of dex. The study was conducted with 199 intermediate fit patients with Revlimid and dexamethasone (Rd) induction (9 cycles) and Revlimid (R) maintenance until progression compared to Rd induction and Rd […]